GEN Exclusives

More »

The Lists

More »
Jan 20, 2014

Top 25 M&A Deals of 2013

Find out which big fish were devoured by larger ones last year.

Top 25 M&A Deals of 2013

Most 2013 deals involved big biotechs, and even several big pharmas, snapping up smaller biopharmas. [© Yuri Arcurs - Fotolia.com]

  • #10. Santarus

    Acquired by: Salix Pharmaceuticals

    Price: $2.6 billion

    Deal Status: Announced November 7; deal expected to close in the first quarter of 2014.

    Premium: 36% premium over Santarus' November 6, 2013 closing price of $23.53 per share and an approximately 39% premium over Santarus' average closing stock price for the prior 30-trading day period, based on deal price of $32 per share.

  • #9. Patheon

    Acquired by: NewCo12

    Price: Combination of deals totaling more than $2.6 billion13

    Deal Status: Announced November 19; deals expected to be completed in the first half of 2014.

    Premium: 64% above Patheon's closing share price on November 18, based on deal price of $9.32 per share

  • #8. Algeta

    Acquired by: BayerHealthCare

    Price: $2.9 billion

    Deal Status: Algeta board of directors on December 19 unanimously recommends deal approval by shareholders. Bayer expects to close the transaction during the first quarter of 2014.

    Premium: 37% premium to Algeta's closing share price on November 25, and 48% premium to the three-month volume weighted average stock price on November 25, the last trading day before the November 26 announcement of Bayer's preliminary acquisition proposal

  • #7. ViroPharma

    Acquired by: Shire

    Price: About $4.2 billion

    Deal Status: Announced November 11; deal expected to close by first quarter of 2014 “or as soon as possible thereafter.”

    Premium: 27% premium to ViroPharma's closing share price on November 8, 2013, the last trading day prior to announcement, and a 64% premium to ViroPharma's unaffected share price of $30.47 on September 12, 2013, based on deal price of $50 per share

  • #6. Bristol-Myers Squibb (BMS; Diabetes development operations)14

    Acquired by: AstraZeneca15

    Price: Up to $4.3 billion—including $2.7 billion upfront, up to $1.4 billion tied to regulatory and sales-based milestones, and up to $225 million tied to the transfer of assets. AstraZeneca also agreed to pay BMS royalties on set sales through 2025

    Deal Status: Announced December 19; deal expected to close in first quarter 2014.

    Premium: N/A

  • #5. Warner Chlicott

    Acquired by: Actavis

    Price: About $8.5 billion

    Deal Status: Completed October 1

    Premium: Warner Chilcott shareholders will receive, for each share they own, 0.160 shares in the combined company. Based on Actavis' closing price of $125.50 on May 17, that equals $20.08 per Warner Chilcott share—43% above the company’s average $14 per-share price for the 30 trading days ending May 9, the day before Warner Chilcott disclosed preliminary talks with Actavis; and 34% above Warner Chilcott’s closing May 9 price of $15.01.

  • #4. Elan

    Acquired by: Perrigo

    Price: About $8.6 billion

    Deal Status: Completed December 18

    Premium: 10.5% above Elan’s closing ADR stock price July 26 of $14.93 on the New York Stock Exchange, based on deal price of $16.50 per share

  • #3. Bausch + Lomb

    Acquired by: Valeant Pharmaceuticals International

    Price: $8.7 billion16

    Deal Status: Completed August 6

    Premium: N/A

  • #2. Onyx Pharmaceuticals

    Acquired by: Amgen

    Price: $10.4 billion17

    Deal Status: Completed October 1

    Premium: 44% premium above the $86.84 per-share closing price of Onyx shares on June 28, the last full trading day before speculation surfaced about Amgen’s interest in snapping up the company, based on the deal price of $125 per share

  • #1. Life Technologies

    Acquired by: Thermo Fisher Scientific

    Price: $13.6 billion18

    Deal Status: Announced April 15. Won European Commission clearance in November, after Thermo Fisher agreed to shed its cell culture (sera and media), gene modulation, and magnetic beads businesses. Deal expected to win all remaining regulatory approvals and close in 2014.

    Premium: 12% above Life Tech’s closing price of $68 per share in April 12 trading on NASDAQ, based on $76 per share deal price



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?